Overview
The second issue of volume 40 for 2026 includes:
– Evidence-to-Decision Framework to Prioritize PD-1 and PD-L1 Immune Checkpoint Inhibitors for the WHO Model List of Essential Medicines to Treat Adults with Solid Tumors in the Palliative First-Line Setting: Pilot Study
Consultation Documents
– Bioequivalence For Immediate Release Oral Dosage Forms
– Model quality assurance system for procurement agencies
– Points to consider on integration of environmental sustainability strategies and metrics into pharmaceutical manufacturing
Anatomical Therapeutic Chemical/Defined Daily Dose (ATC/DDD) Classification
– ATC/DDD Classification (Temporary)
– ATC/DDD Classification (Final)
Volume 40, issue 2, concludes with the International Nonproprietary Names (INN) List – Proposed INN List No. 135
WHO Team
Health Systems, Access and Data (HSD),
Medicines and Health Products, Policies and Standards (HPS),
Regulation and Prequalification (RPQ)
Editors
World Health Organization
Number of pages
494
Reference numbers
ISBN: 9789240123991
Copyright
English (United States) 
English (UK)